Patients affected by type 2 diabetes can benefit from improved lipid profiles and reduced possibilities of cardiovascular events with the use of SGLT2 inhibitors and GLP-1 receptor agonists (24). The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.